Cardiovascular
Auxilius Pharma to launch Phase Ib anti-anginal trial after IND application
Auxilius Pharma will be submitting an investigative new drug (IND) application for AUX-001 with plans to initiate a Phase Ib…
Sequana’s DSR therapy shows promise in heart failure patients
Belgium-based Sequana Medical has released data from the Phase I/II MOJAVE study in the US, which is evaluating its direct…
AstraZeneca kick-starts Phase III COPD trial for Breztri
AstraZeneca has launched a Phase III THARROS trial to evaluate the efficacy of its triple-combination inhaled therapy Breztri (budesonide /…
Myocardial Infarction: Three drug trials to watch in 2024
Myocardial infarction (MI), known commonly as a heart attack, is one of the major causes of death globally and can…
Aria CV implants first patient with pulmonary hypertension system
Aria CV has kicked off its ASPIRE PH trial and successfully implanted the first patient with its system to treat…
BiVACOR secures $13m for total artificial heart programme
US-based BiVACOR has been awarded $13m from the Australian Government’s Medical Research Future Fund (MRFF) to advance its total artificial…
PCSK9 inhibitor Alirocumab proves effective in paediatric familial hypercholesterolemia
Heterozygous familial hypercholesterolemia (HeFH) is an autosomal dominant disorder characterised by elevated levels of low-density lipoprotein cholesterol (LDL-C), leading to…
CSL’s ‘big’ post-heart attack drug fails in Phase III trial
Australian CSL has released topline results from the Phase III AEGIS-II trial of CSL112 in patients following an acute myocardial…
Zymedi doses first subject in Phase I PAH treatment trial
Korean biotech venture-backed company Zymedi has dosed the first subject in a Phase I clinical trial of a monoclonal antibody,…
J&J’s Varipulse system achieves freedom for atrial arrhythmia recurrence
Biosense Webster, part of Johnson & Johnson MedTech, has reported 12-month results from the inspIRE and admIRE trials demonstrating month…